行情

SNSS

SNSS

Sunesis Pharma
NASDAQ

实时行情|Nasdaq Last Sale

0.4200
-0.0078
-1.82%
已收盘, 16:59 04/02 EDT
开盘
0.4399
昨收
0.4278
最高
0.5000
最低
0.4050
成交量
90.48万
成交额
--
52周最高
1.770
52周最低
0.1951
市值
4,678.51万
市盈率(TTM)
-1.4508
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测SNSS价格均价为2.667,最高价位6.00,最低价为1.000。

EPS

SNSS 新闻

更多
  • Is Sunesis Pharmaceuticals (SNSS) Stock Outpacing Its Medical Peers This Year?
  • Zacks · 15小时前
  • Edited Transcript of SNSS earnings conference call or presentation 10-Mar-20 8:30pm GMT
  • Thomson Reuters StreetEvents · 03/26 21:08
  • Is Sunesis Pharmaceuticals (SNSS) Outperforming Other Medical Stocks This Year?
  • Zacks · 03/17 16:30
  • Earnings Beat: Sunesis Pharmaceuticals, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
  • Simply Wall St. · 03/13 17:56

所属板块

生物技术和医学研究
+3.33%
制药与医学研究
+2.79%

热门股票

代码
价格
涨跌幅

SNSS 简况

Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company’s lead programs are Vecabrutinib, SNS-510 and TAK-580. The Company also offers Vosaroxin, an anticancer quinolone derivative (AQD), which is used for the treatment of acute myeloid leukemia (AML). Vecabrutinib is a selective, reversible, non-covalent binding inhibitor of Bruton's tyrosine kinase (BTK) inhibitors. SNS-510 is a phosphoinositide dependent protein kinase 1 (PDK1) inhibitors. TAK-580 is an oral, investigative drug selective for pan-Raf kinase inhibition, in patients with relapsed or refractory solid tumors.
展开

微牛提供Sunesis Pharmaceuticals, Inc.(NASDAQ-SNSS)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的SNSS股票新闻,以帮助您做出投资决策。